AOD-9604: weight-loss evidence, safety and UK status
Get practical health advice and updates on Puri Pharmacy services straight to your inbox.
AOD-9604 is an investigational peptide developed as a potential obesity treatment. The larger human weight-loss trial did not show a statistically significant benefit over placebo for its primary weight-loss outcome. It is not a licensed UK weight-loss medicine, and claims that it safely targets stubborn fat go beyond the clinical evidence.
- There is negative human evidence to address, not simply an absence of research.
- A tolerability paper is not proof of effective weight loss.
- Evidence from oral or intravenous studies does not validate a subcutaneous injection regimen.
- AOD-9604 is prohibited at all times under the 2026 WADA List.
Puri Pharmacy’s position: we do not sell, supply or prescribe AOD-9604. Its proposed wellness uses remain investigational. We recognise that some readers may already use research peptides and want them to seek advice without judgement. Licensed peptide medicines exist, but that does not make this compound licensed or establish the quality of an online product.
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide related to a fragment of human growth hormone. It is not full-length growth hormone. The FDA’s December 2024 scientific briefing reviews its development, chemistry and evidence for obesity.
The research idea was to investigate particular effects of a fragment rather than assume that it behaves like the entire hormone. That is a hypothesis to test. It does not justify marketing language suggesting that someone can select the desirable effects of a hormone while removing every unwanted effect.
AOD-9604 is also not simply interchangeable with every product described as “HGH fragment”. Names, modifications and preparation details matter. A study must match the substance being discussed before its findings can meaningfully support a claim.
What happened in the weight-loss trial?
The FDA briefing describes the OPTIONS study: 502 adults with obesity were randomised to oral AOD-9604 or placebo within a 24-week programme that also included diet and exercise support. The primary weight-loss comparison at 12 weeks was not statistically significant. Commercial development for obesity was subsequently stopped. FDA review of the trial evidence.
This should not be reframed as “it worked, but more research is needed”. It is evidence that the study did not demonstrate the intended advantage. Equally, it is not proof that no possible preparation could ever have any biological effect. The fair conclusion is narrower: the trial did not establish the advertised weight-loss benefit.
Why the placebo comparison matters
Participants may lose weight during a study because of changes in food intake, activity, support or other factors. A headline reporting weight lost in a treatment group alone cannot tell us how much, if any, was attributable to the treatment.
The comparison group is therefore central. If both groups receive the same structured support, the study can examine whether the added intervention improves the outcome. Selecting the most impressive before-and-after number while leaving out the comparison makes the evidence appear stronger than it is.
It is also important to distinguish the planned main outcome from exploratory findings. A favourable observation in a subgroup or at another time point cannot simply replace a failed primary outcome without explaining the change in question. That is a general research principle, not an accusation that every positive claim is deliberately deceptive.
Why do some articles call AOD-9604 safe?
A 2013 paper by Stier and colleagues summarised safety data from six trials involving 893 participants. The authors reported favourable tolerability and no significant effect on IGF-1 or glucose tolerance in the studied settings. The paper included oral and intravenous exposure; it was not a validation of modern self-injected wellness courses. Two authors had affiliations with the developer, Metabolic Pharmaceuticals.
Those findings deserve acknowledgement, with their limits attached. A paper focused on tolerability can help describe what happened during those studies. It cannot, by itself, establish effective weight loss, every long-term risk or the quality of a different product. Industry involvement is relevant context for appraisal; it does not automatically invalidate the observations.
“No signal detected” is not “every risk excluded”
Studies can miss uncommon effects or effects that take longer to emerge. They may exclude people with particular health conditions, and the preparation used may differ from products later sold online. The relevant question is not whether any study sounded reassuring, but how closely its population, exposure and follow-up match the claim now being made.
It would therefore be misleading to promise that AOD-9604 has no hormonal, metabolic or immune risks. It would also be misleading to invent a precise adverse-effect rate where adequate data do not exist. A careful account states what was measured and leaves unresolved questions unresolved.
Do injections solve the disappointing oral results?
No such conclusion follows. The FDA review identified no human efficacy data for the proposed subcutaneous or transdermal routes within its review. That gap does not establish that injections work better. FDA assessment.
Changing route changes the intervention that needs testing. An explanation about absorption is a reason to investigate, not a replacement for a clinical trial. A convincing study would still need to establish benefit, appropriate exposure, adverse effects and the circumstances in which the findings apply.
There is also no basis here for recommending injection into a particular body area to remove fat there. A claim about “targeting belly fat” needs evidence about the specific outcome and route. A demonstration video or a seller’s protocol cannot supply missing trial results.
What does the regulator say about safety concerns?
The FDA’s compounding safety information raises concerns about potential immune reactions, peptide impurities and limited safety information for AOD-9604. Reports of serious events do not establish causation or give a reliable personal risk estimate. They do, however, make an unqualified “proven safe” claim inappropriate.
This US scientific information informs evidence appraisal; it is not UK legislation. Safety, approval and supply legality are separate questions. A substance can have a plausible mechanism and still lack adequate clinical evidence, or have favourable short-term observations without a marketing authorisation for the claimed use.
Who should avoid experimental self-use?
There is no established group of healthy consumers for whom a research-product course can be certified safe. Pregnancy, breastfeeding, being under 18, significant illness, previous serious reactions or concurrent medicines are reasons to seek individual advice. They are not the only circumstances that matter.
This is not an invented prescribing checklist for a licensed product. The absence of a known problem on a short list does not clear someone for use. Do not stop prescribed treatment or combine additional peptides in an attempt to manage uncertainty yourself.
Is AOD-9604 legal in the UK?
AOD-9604 is not a licensed UK obesity treatment. “Unlicensed” does not mean illegal in every circumstance: Regulation 167 provides a restricted specials framework. That does not authorise general wellness sales. MHRA classification considers the product’s claims and properties, not just a research label.
What about athletes?
AOD-9604 is named among growth hormone fragments under S2 in the 2026 WADA Prohibited List. It is prohibited in and out of competition. Follow UKAD guidance; an off-season course is not exempt.
Can blood tests make its use safe?
No. A test may address a particular clinical concern after exposure, but it cannot authenticate a product or establish effectiveness. A normal IGF-1 result, for example, cannot answer whether an intervention improves weight-related health or whether a supplied vial is suitable for human use.
There is no evidence-based universal monitoring schedule that converts experimental use into approved care. The choice of tests should follow symptoms, history and clinical judgement, rather than a package intended to reassure someone before continuing an unproven course.
A more useful way to approach a weight concern
Start by defining the concern: sustained weight change, a change in waist size, physical function or symptoms. These are related but different questions. An assessment can consider medical history, medicines, nutrition, activity, sleep and established treatment options without assuming that a peptide is the answer.
- Was the outcome measured in humans with a comparable problem?
- Did the treatment outperform an appropriate comparison group?
- Does the route and preparation match the product being discussed?
- Is a safety paper being used to imply effectiveness?
- What useful outcome would change the decision, and what remains unknown?
If you have already used AOD-9604, tell the clinician the product name, source, timing and any symptoms. Bring the packaging or photographs if available. Call 999 for sudden tongue or throat swelling or breathing difficulty, in line with NHS guidance.
Frequently asked questions
Is AOD-9604 the same as growth hormone?
No. Being related to a fragment does not make the whole-hormone evidence applicable, or establish that every unwanted effect has been removed.
Does a negative trial mean the substance has no biological activity?
No. It means the intended benefit was not demonstrated under the conditions tested. Biological activity and worthwhile clinical benefit are different questions.
Can oral safety data prove that an injection course is safe?
No. Route, preparation and exposure matter, and the course needs its own relevant evidence.
Does an unchanged blood marker prove weight loss is safe?
No. One marker cannot capture all potential harms, and it does not establish that the intervention caused a useful outcome.
Can Puri Pharmacy provide AOD-9604?
No. We do not sell, supply or prescribe it. Our role is education and appropriate signposting.
Key takeaways
- The larger trial’s negative result belongs in any balanced account.
- Tolerability and effectiveness are separate evidence questions.
- Changing route does not resolve missing evidence.
- Research labels and normal tests are not safety certificates.
Evidence summary
This summary draws on the studies and official guidance linked above.
- What human evidence shows: The larger oral weight-loss trial provides a direct human test of the claim and did not show a significant advantage at its primary endpoint.
- What is not established: Tolerability findings do not establish effective weight loss; switching to an injection does not fix the evidence gap.
- Main safety uncertainties: Safety evidence from one route and preparation does not cover every injectable product or course.
- What would change the assessment: A well-controlled trial of the proposed preparation and route demonstrating meaningful, sustained benefit with adequate safety data.
Continue reading
- How to judge peptide evidence
- Why the route and preparation matter
- Retatrutide: promising findings, safety and UK status
Follow Rahul’s peptide analysis
Subscribe to Puri Pharmacy’s health updates, including Rahul Puri’s explanations of peptide evidence, safety and UK regulation. This is an educational newsletter, not access to peptide treatment.
By subscribing, you agree to receive Puri Pharmacy’s health emails. Read our privacy policy.
Have a question about a claim? Use our contact form and include the article or study you want explained. Do not post personal health information in public comments. These articles provide education; Puri does not supply the experimental research peptides discussed here.
For symptoms or an individual treatment decision, seek appropriate clinical advice. For urgent symptoms, seek urgent medical care directly rather than waiting for a pharmacy reply.
